Thank you for sharing!

Your article was successfully shared with the contacts you provided.
PHILADELPHIA (AP) _ Federal regulators sued Cephalon Inc. on Wednesday, accusing the company of illegally blocking the sale of low-cost generics to protect its biggest moneymaking drug. The U.S. Federal Trade Commission has accused Cephalon of “anticompetitive conduct” to inhibit generic competition against its drug Provigil. Regulators said the company paid four pharmaceutical firms more than $200 million to halt sales of generic versions of Provigil until 2012. Provigil, which accounts for about half of Cephalon’s total sales, treats excessive sleepiness in patients with sleep apnea, narcolepsy, and shift-work sleep disorder. “Cephalon prevented competition to Provigil by agreeing to share its future monopoly profits with generic drug-makers poised to enter the market, in exchange for delayed generic entry,” FTC Bureau of Competition director Jeffrey Schmidt said in a statement. “Such conduct is at the core of what the antitrust laws proscribe.” But Cephalon defended its agreements, saying the deals reached in late 2005 and early 2006 settled patent infringement litigation. “We believe they fully comply with both the spirit and letter of the antitrust laws,” the company said in a statement. Cephalon also said the settlements “confer a meaningful benefit to U.S. consumers by providing for the entry of generic modafinil three years early.” The FTC said the four drug-makers had been preparing to market their own generic versions of Provigil or had challenged the validity of the only remaining patent on the drug. With Cephalon’s settlement, the FTC said, it was able to get the drug-makers to stop the patent challenge. The four pharmaceutical firms are Teva Pharmaceuticals USA Inc., Ranbaxy Pharmaceuticals, Inc., Mylan Pharmaceuticals Inc., and Barr Laboratories, Inc. Shares of Frazer-based Cephalon fell $1.03 to $57.44 on Wednesday.

Want to continue reading?
Become a Free ALM Digital Reader.

Benefits of a Digital Membership:

  • Free access to 1 article* every 30 days
  • Access to the entire ALM network of websites
  • Unlimited access to the ALM suite of newsletters
  • Build custom alerts on any search topic of your choosing
  • Search by a wide range of topics

*May exclude premium content
Already have an account?


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.